These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
88 related articles for article (PubMed ID: 21155900)
1. Salvage therapy for refractory rejection and persistence of donor-specific antibodies after intestinal transplantation using the proteasome inhibitor bortezomib. Gerlach UA; Schoenemann C; Lachmann N; Koch M; Pascher A Transpl Int; 2011 May; 24(5):e43-5. PubMed ID: 21155900 [No Abstract] [Full Text] [Related]
2. The impact of proteasome inhibition on alloantibody-producing plasma cells in vivo. Diwan TS; Raghavaiah S; Burns JM; Kremers WK; Gloor JM; Stegall MD Transplantation; 2011 Mar; 91(5):536-41. PubMed ID: 21283064 [TBL] [Abstract][Full Text] [Related]
3. Proteasome inhibition for antibody-mediated rejection. Everly JJ; Walsh RC; Alloway RR; Woodle ES Curr Opin Organ Transplant; 2009 Dec; 14(6):662-6. PubMed ID: 19667989 [TBL] [Abstract][Full Text] [Related]
4. Successful treatment with bortezomib of a refractory humoral rejection of the intestine after multivisceral transplantation. Island ER; Gonzalez-Pinto IM; Tsai HL; Ruiz P; Tryphonopoulos P; Gonzalez ML; Solano JP; Rossique M; Selvaggi G; Tekin A; Smith LJ; Tzakis AG Clin Transpl; 2009; ():465-9. PubMed ID: 20524316 [TBL] [Abstract][Full Text] [Related]
5. Proteasome inhibitor treatment of antibody-mediated allograft rejection. Woodle ES; Alloway RR; Girnita A Curr Opin Organ Transplant; 2011 Aug; 16(4):434-8. PubMed ID: 21753709 [TBL] [Abstract][Full Text] [Related]
8. The role of proteasome inhibition with bortezomib in the treatment of antibody-mediated rejection after kidney-only or kidney-combined organ transplantation. Flechner SM; Fatica R; Askar M; Stephany BR; Poggio E; Koo A; Banning S; Chiesa-Vottero A; Srinivas T Transplantation; 2010 Dec; 90(12):1486-92. PubMed ID: 21042239 [TBL] [Abstract][Full Text] [Related]
9. Proteasome inhibition drastically but reversibly impairs murine lymphocyte development. Maseda D; Meister S; Neubert K; Herrmann M; Voll RE Cell Death Differ; 2008 Mar; 15(3):600-12. PubMed ID: 18188168 [TBL] [Abstract][Full Text] [Related]
10. Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites. Pekol T; Daniels JS; Labutti J; Parsons I; Nix D; Baronas E; Hsieh F; Gan LS; Miwa G Drug Metab Dispos; 2005 Jun; 33(6):771-7. PubMed ID: 15764713 [TBL] [Abstract][Full Text] [Related]
11. BCL-2 family regulation by the 20S proteasome inhibitor bortezomib. Fennell DA; Chacko A; Mutti L Oncogene; 2008 Feb; 27(9):1189-97. PubMed ID: 17828309 [TBL] [Abstract][Full Text] [Related]